Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia
To the Editor:
Acute myeloid leukemia (AML) is a heterogeneous malignancy characterized by chromosomal aberrations and somatic mutations that identify biologically distinct subsets and guide risk stratification for therapy. 1 Treatment-associated changes in clonal architecture are common in AML, with emergence or clearance of specific sub-clones driving sensitivity and resistance to therapy. Therefore, the molecular characterization of emerging clones may facilitate the selection of optimal targeted therapies and rational combinations.
Venetoclax, a selective BCL-2 inhibitor, induced a complete response or complete response with incomplete blood recovery (CR/CRi) in 6/32 (19%) patients with AML who either had relapsed/refractory disease or were medically unfit for intensive chemotherapy. 2 In this report, we present a comparison of genetic biomarkers observed in pre-and post-treatment specimens from 29 of the 32 patients enrolled on this phase II study. Measurable reduction in bone marrow (BM) blast counts was observed in 15/29 (52%) of the patients, including CR/CRi in 6, a ≥50% reduction in BM blasts in 5, and a more modest blast reduction of <50% in 4 (Supporting Information Figure 1 ). The remaining patients (14/29, 48%) had no blast reduction.
We investigated the presence of somatic mutations commonly associated with AML in baseline and end-of-treatment samples. DNA isolated from blood and bone marrow specimens was analyzed by next-generation sequencing using the TruSight Myeloid panel shown in Figure 1A .
At baseline, 10/29 (34%) patients had mutations in isocitrate dehydrogenase 1/2 (IDH1/2) genes. Of these, 7 (70%) had a reduction in BM blasts, including 3 CR/CRi. At baseline, 11/29 (38%) patients had spliceosome mutations in SRSF2 or ZRSR2. Ten (88%) of these patients had a decrease in BM blasts, including 3 CR/CRi. Seven patients had both IDH1/2 and spliceosome mutations with BM blast reductions observed in 6 (86%). In total, 11/14 (79%) patients with mutations in IDH1/2 or SRSF2/ZRSR2 had evidence of BM blast reduction, including 4 CR/CRi, implicating these as possible markers of sensitivity to venetoclax ( Figure 1A ). In summary, our data suggest that SRSF2/ZRSR2 and IDH1/2 mutations may predict sensitivity to venetoclax therapy in AML. Chan et al. previously demonstrated that IDH1/2 mutations can sensitize leukemic cells to venetoclax. 4 However, of the 10 IDH1/2-mutated AML samples assessed in this trial, 7 had co-occurring spliceosome mutations, making it difficult to determine whether only one or both of these mutations together predict for venetoclax sensitivity. Recent findings suggest that IDH2 and SRSF2 mutations cooperate to induce a lethal transplantable myeloproliferative neoplasm. 5 Additionally, SRSF2 mutation is known to induce alternative splicing of genes involved in the apoptotic pathway, a possible link to venetoclax sensitivity. 6 We note that FLT3-ITD or PTPN11 mutations may confer pri- Impact of intranasal fentanyl in nurse initiated protocols for sickle cell vaso-occlusive pain episodes in a pediatric emergency department
Although pain is a universal feature of sickle cell disease (SCD), there is limited evidence to guide management for vasoocclusive pain episodes (VOE). In 2014, the National Heart, Lung, and Blood Institutes (NHLBI) published new guidelines recommending rapid evaluation and treatment of VOE in the acute care setting, with timely pain assessments and repeat analgesia as needed to control pain. Despite these guidelines, delays in administration of parenteral analgesia are common in pediatric emergency departments (ED). Table 1 ).
No adverse events including over-sedation or respiratory depression occurred during the study. The most common side effects included complaints of nasal burning and irritation after administration.
